Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Cited by (718)

Items 101–200 of 718

1. Profiling vaccine believers and skeptics in nurses: A latent profile analysis
   Cyrus Lap Kwan Leung, Kin‐Kit Li, Vivian Wan In Wei, Arthur Tang, Samuel Yeung Shan Wong, Shui Shan Lee, Kin On Kwok · 2021 · International Journal of Nursing Studies
2. Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study
   Stuti Pramod, Dhanajayan Govindan, Premkumar Ramasubramani, Sitanshu Sekhar Kar, Rakesh Aggarwal, JIPMER vaccine effectiveness study group, Nandhini Manoharan, Palanivel Chinnakali, Mahalakshmy Thulasingam, Sonali Sarkar et al. · 2022 · Vaccine
3. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine
   Athanasios G. Michos, Elizabeth‐Barbara Tatsi, Filippos Filippatos, Charilaos Dellis, Dimitra‐Maria Koukou, Vasiliki Efthymiou, Evangelia Kastrinelli, Aimilia Mantzou, Vasiliki Syriopoulou · 2021 · Vaccine
4. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
   Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese N. Tripler, Lupeng Ye et al. · 2022 · Nature Communications
5. Increased airborne transmission of COVID-19 with new variants, Implications for health policies
   Bertrand R. Rowe, André Canosa, Amina Meslem, Frantz Rowe · 2022 · Building and Environment
6. Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern
   Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi, Prajna Tripathi, Kamal Kumar, Shashank Manohar Nambiar, Rajiv Pathak · 2025 · Vaccines
7. Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
   Piotr Rzymski, Monika Pazgan−Simon, Krzysztof Adam Simon, Tadeusz Wojciech Łapiński, Dorota Zarębska‐Michaluk, Barbara Szczepańska, Michał Chojnicki, Iwona Mozer‐Lisewska, Robert Flisiak · 2021 · Vaccines
8. Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
   Claudius Speer, Matthias Schaier, Christian Nußhag, Maximilian Töllner, Mirabel Buylaert, Florian Kälble, Paula Reichel, Julia Grenz, Caner Süsal, Martin Zeier et al. · 2021 · Vaccines
9. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)
   Paolo Basso, Corrado Negro, Luca Cegolon, Francesca Larese Filon · 2022 · Viruses
10. Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients
    Giulia Di Felice, Giovanni Visci, Federica Teglia, Marco Angelini, Paolo Boffetta · 2022 · eLife
11. Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
    Beomki Lee, Jae‐Hoon Ko, Ji‐Ho Park, Hee‐Won Moon, Jin Yang Baek, Sunhee Jung, Hee-Young Lim, Kyung-Chang Kim, Kyungmin Huh, Sun Young Cho et al. · 2022 · Frontiers in Cellular and Infection Microbiology
12. Activities in Namibia to Limit the Prevalence and Mortality from COVID-19 Including Community Pharmacy Activities and the Implications
    Dan Kibuule, Lahya Nambahu, Israel Abebrese Sefah, Amanj Baker Kurdi, Thuy Nguyen Thi Phuong, Hye-Young Kwon, Brian Godman · 2021 · Scholars Academic Journal of Pharmacy
13. Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan
    Yosuke Hirotsu, Masao Omata · 2021 · PLoS Pathogens
14. Decreased memory B cell frequencies in COVID‐19 delta variant vaccine breakthrough infection
    Matthew Zirui Tay, Angéline Rouers, Siew‐Wai Fong, Yun Shan Goh, Yi‐Hao Chan, Zi Wei Chang, Weili Xu, Chee Wah Tan, Wan Ni Chia, Anthony Torres‐Ruesta et al. · 2022 · EMBO Molecular Medicine
15. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Zijing Jia, Kang Wang, Minxiang Xie, Jiajing Wu, Yaling Hu, Yunjiao Zhou, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2024 · Protein & Cell
16. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Kang Wang, Yunlong Cao, Yunjiao Zhou, Jiajing Wu, Zijing Jia, Yaling Hu, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2021 · medRxiv
17. Elucidating causes of COVID-19 infection and related deaths after vaccination
    Vijay Kumar Jain, Karthikeyan Parthasarathy Iyengar, Pranav Ish · 2021 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
18. Breakthrough Infection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Delhi: A Single-Institution Study
    Pragya Sharma, Suruchi Mishra, Saurav Basu, Neha Tanwar, Rajesh Kumar · 2021 · Cureus
19. NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.
    Debashis Dutta, Jianuo Liu, Huangui Xiong · 2022 · PubMed Central
20. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2–Naive Residents of Nursing Homes
    Pieter Pannus, Kristof Y. Neven, Stéphane De Craeye, Leo Heyndríckx, Sara Vande Kerckhove, Daphnée Georges, Johan Míchiels, Antoine Francotte, Marc Van den Bulcke, Maan A. Zrein et al. · 2021 · Clinical Infectious Diseases
21. Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
    Cho, Alice, Muecksch, Frauke, Schaefer-Babajew, Dennis, Wang, Zijun, Finkin, Shlomo, Gaebler, Christian, Ramos, Victor, Cipolla, Melissa, Mendoza, Pilar, Agudelo, Marianna et al. · 2021
22. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
    Yajun Shu, Jianfeng He, Rongjuan Pei, Peng He, Zhuhang Huang, Shaomin Chen, Zhiqiang Ou, Jinglong Deng, Pei-Yu Zeng, Jian Zhou et al. · 2021 · Chinese Medical Journal
23. Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
    Mohammed Ghalib Enayathullah, Yash Parekh, Sarena Banu, Sushma Ram, Ramakrishnan Nagaraj, Bokara Kiran Kumar, Mohammed M. Idris · 2022 · Scientific Reports
24. Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization
    Qiong Wang, Sheng‐Bao Ye, Zhijian Zhou, A‐Ling Song, Xi Zhu, Jia‐Mei Peng, Rui‐Min Liang, Chen‐Hui Yang, Xiaowei Yu, Xun Huang et al. · 2022 · Journal of Medical Virology
25. Accuracy and real life performance of a novel interferon-γ release assay for the detection of SARS-CoV2 specific T cell response
    Daniela Huzly, Marcus Panning, Franziska Smely, Martin Enders, Johanna Komp, Valeria Falcone, Daniel Steinmann · 2022 · Journal of Clinical Virology
26. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
    Nasikarn Angkasekwinai, Jaturong Sewatanon, Suvimol Niyomnaitham, Supaporn Phumiamorn, Kasama Sukapirom, Sompong Sapsutthipas, Rujipas Sirijatuphat, Orasri Wittawatmongkol, Sansnee Senawong, Surakameth Mahasirimongkol et al. · 2022 · Vaccine X
27. Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review
    Shilpa Gopinath, Angela Ishak, Naveen Dhawan, Sujan Poudel, Prakriti Singh Shrestha, Prabhjeet Singh, Emily Xie, Peggy Tahir, Sima Marzaban, Jack Michel et al. · 2022 · Tropical Medicine and Infectious Disease
28. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals
    Gajanan N. Sapkal, Pragya Dhruv Yadav, Rima Rakeshkumar Sahay, Gururaj Rao Deshpande, Nivedita Gupta, Dimpal A. Nyayanit, Deepak Y. Patil, Anita M. Shete, Sanjay Kumar, Priya Abraham et al. · 2021 · Journal of Travel Medicine
29. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
    Dale Kitchin, Simone I. Richardson, Mieke A. van der Mescht, Thopisang P. Motlou, Nonkululeko B. Mzindle, Thandeka Moyo-Gwete, Zanele Makhado, Frances Ayres, Nelia P. Manamela, Holly Spencer et al. · 2022 · Cell Reports Medicine
30. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
    Petra Mlčochová, Steven A. Kemp, Mahesh Shanker Dhar, Guido Papa, Bo Meng, Swapnil Mishra, Charles Whittaker, Thomas A. Mellan, Isabella Ferreira, Rawlings P. Datir et al. · 2021 · Greater South Information System
31. The E3 ligase TRIM22 restricts SARS-CoV-2 replication by promoting proteasomal degradation of NSP8
    Lujie Fan, Yuzheng Zhou, Xiafei Wei, Wei Feng, Huimin Guo, Yunfei Li, Xiang Gao, Jian Zhou, Yanling Wen, Yezi Wu et al. · 2024 · mBio
32. 2021 Interim Guidance to Health Care Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19
    Antony Hsu, Comilla Sasson, Peter J. Kudenchuk, Dianne L. Atkins, Khalid Aziz, Lance B. Becker, Robert Allen Berg, Farhan Bhanji, Steven M. Bradley, Steven C. Brooks et al. · 2021 · Circulation Cardiovascular Quality and Outcomes
33. RETRACTED ARTICLE: Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients
    Sabine Hazan, Sonya Davé, Anoja W. Gunaratne, Sibasish Dolai, Robert Llewellyn Clancy, Peter Andrew McCullough, Thomas Julius Borody · 2022 · Future Microbiology · Retracted
34. Differentials in the characteristics of COVID-19 cases in Wave-1 and Wave-2 admitted to a network of hospitals in North India
    Sandeep Budhiraja, Abhaya Indrayan, Mona Aggarwal, Vinita Jha, Dinesh Jain, Bansidhar Tarai, Poonam Das, Bharat Bhushan Aggarwal, RS Mishra, Supriya Bali et al. · 2021 · medRxiv
35. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
    Michael S. Seaman, Mark Jacob Siedner, Julie Boucau, Christy L. Lavine, Fadi Ghantous, May Yee Liew, Josh Mathews, Arshdeep Singh, Caitlin Marino, James Regan et al. · 2022 · JCI Insight
36. COVID-19 variants in India: Potential role in second wave and impact on vaccination
    Shekhar Kunal, Aditi, Kashish Gupta, Pranav Ish · 2021 · Heart & Lung
37. Variants of concern responsible for SARS‐CoV‐2 vaccine breakthrough infections from India
    Urvashi Balbir Singh, Mercy Rophina, Rama Chaudhry, Vigneshwar Senthivel, Kiran Bala, Rahul C. Bhoyar, Bani Jolly, Nayer Jamshed, Mohamed Imran, Ritu Gupta et al. · 2021 · Journal of Medical Virology
38. BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant
    Ludwig Knabl, Hye‐Kyung Lee, Manuel Wieser, Anna Mur, August Felix Zabernigg, Ludwig Knabl, Simon Rauch, Matthias Böck, Jana Schumacher, Norbert Kaiser et al. · 2022 · Communications Medicine
39. Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis
    Xiaoming Wu, Haijiao Jing, Chengyue Wang, Yufeng Wang, Nan Zuo, Tao Jiang, Valerie Anne Novakovic, Jialan Shi · 2022 · Frontiers in Microbiology
40. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
    Jonathan L. Torres, Gabriel Ozorowski, Emanuele Andreano, Hejun Liu, Jeffrey Copps, Giulia Piccini, Lorena Donnici, Matteo Conti, Cyril Planchais, Delphine Planas et al. · 2022 · Proceedings of the National Academy of Sciences
41. Theaflavin 3-gallate inhibits the main protease (Mpro) of SARS-CoV-2 and reduces its count in vitro
    Mahima Chauhan, Vijay Kumar Bhardwaj, Asheesh Kumar, Vinod Kumar, Pawan Kumar, Mohammed Ghalib Enayathullah, Jessie Thomas, Joel George, Bokara Kiran Kumar, Rituraj Purohit et al. · 2022 · Scientific Reports
42. Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers
    Marie Tré‐Hardy, Roberto Cupaiolo, Alain Wilmet, Ingrid Beukinga, Laurent Blairon · 2021 · Journal of Infection
43. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
    Krystallenia Paniskaki, Moritz Anft, Toni Luise Meister, Corinna Sophie Marheinecke, Stephanie Pfaender, Sarah Skrzypczyk, Felix Sebastian Seibert, Constantin J. Thieme, Margarethe Konik, Sebastian Dolff et al. · 2022 · Frontiers in Immunology
44. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152
    Pragya Dhruv Yadav, Rima Rakeshkumar Sahay, Gajanan N. Sapkal, Dimpal A. Nyayanit, Anita M. Shete, Gururaj Rao Deshpande, Deepak Y. Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham et al. · 2021 · Journal of Travel Medicine
45. Selected Plant Triterpenoids and Their Derivatives as Antiviral Agents
    Martina Wimmerová, Uladzimir Bildziukevich, Zdeněk Wimmer · 2023 · Molecules
46. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
    Kimiyasu Shiraki, Noriaki Sato, Kaoru Sakai, Shirou Matsumoto, Richard H. Kaszynski, Masaya Takemoto · 2022 · Pharmacology & Therapeutics
47. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
    Thomas Lechmere, Luke B. Snell, Carl Graham, Jeffrey Seow, Zayed A. Shalim, Themoula Charalampous, Adela Alcolea-Medina, Rahul Batra, Gaia Nebbia, Jonathan D. Edgeworth et al. · 2022 · mBio
48. ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
    Maja Cokarić Brdovčak, Jelena Materljan, Marko Šustić, Sanda Ravlić, Tina Ružić, Berislav Lisnić, Karmela Miklić, Ilija Brizić, Marina Pribanić Matešić, Vanda Juranić Lisnić et al. · 2022 · European Journal of Immunology
49. Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients
    Rubén Torres, Luis Guillermo Toro, María Eugenia Sanhueza, Eduardo Lorca, Mireya Ortiz, Jacqueline Pefaur, René Clavero, Eduardo A. Machuca, Fernando González, Patricia Herrera et al. · 2022 · Kidney International Reports
50. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site
    Vera J. E. van Vliet, Nhan Huynh, Judith Palà, Ankoor Patel, Alex U. Singer, Cole Slater, Jacky Chung, Mariska van Huizen, Joan Teyra, Shane Miersch et al. · 2022 · PLoS Pathogens
51. Effectiveness of COVID‑19 vaccines and their challenges (Review)
    Gabriella Marfè, Stefania Perna, Arvind Kumar Shukla · 2021 · Experimental and Therapeutic Medicine
52. The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper
    Grigoris Gerotziafas, M. Catalano, Yiannis Theodorou, Patrick Van Dreden, Vincent Maréchal, Alex C. Spyropoulos, Charles Carter, Nusrat Jabeen, Job Harenberg, Ismaı̈l Elalamy et al. · 2021 · Thrombosis and Haemostasis
53. Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences
    Randall J. Olsen, Paul A. Christensen, Scott Wesley Long, Sishir Subedi, Parsa Hodjat, Robert Olson, Marcus Nguyen, James J. Davis, Prasanti Yerramilli, Matthew Ojeda Saavedra et al. · 2021 · American Journal Of Pathology
54. Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India
    Girish Chandra Dash, Subhra Subhadra, Jyotirmayee Turuk, Debaprasad Parai, Sonalika Rath, Jyotsnamayee Sabat, Usha Kiran Rout, Srikanta Kanungo, Hari Ram Choudhary, Rashmi Ranjan Nanda et al. · 2021 · Journal of Medical Virology
55. Continuous Renal Replacement Therapy With oXiris Filter May Not be an Effective Resolution to Alleviate Cytokine Release Syndrome in Non-AKI Patients With Severe and Critical COVID-19
    Kai Kang, Yunpeng Luo, Yang Gao, Jian-Nan Zhang, Changsong Wang, Dongsheng Fei, Wei Zhong Yang, Xianglin Meng, Ming Ye, Yan Gao et al. · 2022 · Frontiers in Pharmacology
56. SARS -CoV-2 T-cell immunity to variants of concern following vaccination
    Kathleen Gallagher, Mark B. Leick, Rebecca C. Larson, Trisha R. Berger, Katelin Katsis, Jennifer Y. Yam, Gabrielle Brini, Korneel Grauwet, MGH COVID-19 Collection & Processing Team, Marcela Valderrama Maus · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
57. Disentangling the causes of mumps reemergence in the United States
    Deven V. Gokhale, Tobias S. Brett, Biao He, Aaron A. King, Pejman Rohani · 2023 · Proceedings of the National Academy of Sciences
58. Potential COVID-19 Endgame Scenarios
    Aaron D. Kofman, Rami Kantor, Eli Y. Adashi · 2021 · JAMA
59. Mouse Models for the Study of SARS-CoV-2 Infection
    Audrey C. Knight, Stephanie A. Montgomery, Craig Fletcher, Victoria Kate Baxter · 2021 · Comparative Medicine
60. Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics
    Ken Asada, Masaaki Komatsu, Ryo Shimoyama, Ken Takasawa, Norio Shinkai, Akira Sakai, Amina Bolatkan, Masayoshi Yamada, Satoshi Takahashi, Hidenori Machino et al. · 2021 · Journal of Personalized Medicine
61. Comparison of analytical sensitivity and efficiency for SARS-CoV-2 primer sets by TaqMan-based and SYBR Green-based RT-qPCR
    Yile Tao, Yang Yue, Guangyu Qiu, Zheng Ji, Martin Spillmann, Zhibo Gai, Qingfa Chen, Michel Bielecki, Michael Huber, Alexandra Trkola et al. · 2022 · Applied Microbiology and Biotechnology
62. Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020–2021)
    Rafael García Carretero, Oscar Vázquez Gómez, Ruth Gil-Prieto, Ángel Gil de Miguel · 2023 · BMC Infectious Diseases
63. The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in April 2021
    Bénédicte Roquebert, Sabine Trombert‐Paolantoni, Stéphanie Haïm‐Boukobza, Emmanuel Lecorché, Laura Verdurme, Vincent Foulongne, Mircea T. Sofonea, Samuel Alizon · 2021 · Eurosurveillance
64. Natural rodent model of viral transmission reveals biological features of virus population dynamics
    Elizabeth J. Fay, Keir M. Balla, Shanley N. Roach, Frances K. Shepherd, Dira S. Putri, Talia D. Wiggen, Stephen A. Goldstein, Mark J. Pierson, Martin T. Ferris, Claire E. Thefaine et al. · 2021 · The Journal of Experimental Medicine
65. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity
    Yu Nakagama, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Domínguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi et al. · 2022 · The Journal of Infectious Diseases
66. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
    Günl, Franziska, Mecate-Zambrano, Angeles, Rehländer, Selina, Hinse, Saskia, Ludwig, Stephan, Brunotte, Linda · 2021 · Vaccines
67. mRNA-based HIV-1 vaccines
    Shamim Ahmed, Alon Herschhorn · 2024 · Clinical Microbiology Reviews
68. Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
    Ignacio Barandalla, Carmen Alvarez-Domı́nguez, Pablo Barreiro, Carmen de Mendoza, Rubén Arístides González Crespo, Vincent Soriano · 2021 · International Journal of Infectious Diseases
69. Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States
    Radhika V. Gharpure, Samira Sami, Johanna Vostok, Hillary Johnson, Noemi Borsay Hall, Anne Foreman, Rebecca T. Sabo, Petra L. Schubert, Hanna M. Shephard, Vance R. Brown et al. · 2021 · Emerging infectious diseases
70. Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides
    Kazuki Z. Yamamoto, Nobuaki Yasuo, Masakazu Sekijima · 2022 · Journal of Chemical Information and Modeling
71. Deep learning based on biologically interpretable genome representation predicts two types of human adaptation of SARS-CoV-2 variants
    Jing Li, Yanan Wu, Sen Zhang, Xiaoping Kang, Tao Jiang · 2022 · Briefings in Bioinformatics
72. Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern
    Luca Murer, Romain Volle, Vardan Andriasyan, Anthony Petkidis, Alfonso Gómez-González, Liliane Yang, Nicole Meili, Maarit Suomalainen, Michael Bauer, Daniela Policarpo Sequeira et al. · 2022 · Current Research in Virological Science
73. Specific Treatment Exists for SARS-CoV-2 ARDS
    Badar A. Kanwar, Asif Khattak, Jong‐Hoon Lee, Jenny Balentine, R. E. Kast, Sang-Suk Oh, Consolato Sergi, Jong‐Hoon Lee · 2021 · Vaccines
74. Rapid test to assess the escape of SARS-CoV-2 variants of concern
    Jacob T. Heggestad, Rhett J. Britton, David Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus Hucknall, Lyra B. Olson, Jack G. Anderson, Anna Mazur, Cameron R. Wolfe et al. · 2021 · Science Advances
75. Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021
    Alexandre Rodrigues Marra, João Luiz Miraglia, Daniel Tavares Malheiros, Yang Guozhang, Vanessa Teich, Elivane da Silva Victor, João Renato Rebello Pinho, Adriana Serra Cypriano, Laura Wanderly Vieira, Miria Polonio et al. · 2022 · Clinical Infectious Diseases
76. The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses
    Sungmin Jung, Jae Hyung Jung, Ji Yun Noh, Woojoong Kim, Soo‐Young Yoon, Jongtak Jung, Eu Suk Kim, Hong Bin Kim, Hee Jin Cheong, Woo Joo Kim et al. · 2022 · Cell Reports
77. Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer
    Daniel Ruben Akiola Sanya, Claudia Cava, Djamila Onésime · 2022 · Human Cell
78. Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
    Bettina Lange, Marlis Gerigk, Tobias Tenenbaum · 2021 · New England Journal of Medicine
79. Rapid Inactivation of SARS-CoV-2 Variants by Continuous and Intermittent Irradiation with a Deep-Ultraviolet Light-Emitting Diode (DUV-LED) Device
    Hiroko Inagaki, Akatsuki Saito, Chiho Kaneko, Hironobu Sugiyama, Tamaki Okabayashi, Shouichi Fujimoto · 2021 · Pathogens
80. Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies
    Jorge Fernández, Nicole Bruneau, Rodrigo Fasce, Héctor San Martín, Monserrat Balanda, Patricia Bustos, Soledad Ulloa, Judith Mora, Eugenio Ramírez V · 2021 · Journal of Medical Virology
81. SARS-CoV-2 transmission during an indoor professional sporting event
    Johannes Pauser, Chantal Schwarz, James Morgan, Jonathan Jantsch, Matthias H. Brem · 2021 · Scientific Reports
82. Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
    AbdulRahman A. Saied, Asmaa A. Metwally, Moses Alobo, Jaffer Shah, Khan Sharun, Kuldeep Dhama · 2022 · International Journal of Surgery
83. Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy
    Zhian Chen, Xin Gao, Di Yu · 2022 · Open Research (University of Surrey)
84. In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals
    Li Li, Muharrem Müftüoğlu, Shaoheng Liang, Mahesh Basyal, Jiangxing Lv, Mehmet Emin Akdogan, Ken Chen, Michael Andreeff, Christopher R. Flowers, Simrit Parmar · 2022 · JCI Insight
85. Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences
    Ali Ahmed Rabaan, Shamsah H. Al-Ahmed, Hawra Albayat, Sara M. Alwarthan, Mashael M. Alhajri, Mustafa A. Najim, Bashayer Mohammed Alshehail, Wasl Al-Adsani, Ali Alghadeer, Wesam A. Abduljabbar et al. · 2023 · Medicina
86. Greater Covid-19 Severity and Mortality in Hospitalized Patients in Second (Delta Variant) Wave Compared to the First: Single Centre Prospective Study in India
    Raghubir Singh Khedar, Kartik Mittal, Harshad C Ambaliya, Alok Vardhan Mathur, Jugal Bihari Gupta, Krishna Kumar Sharma, Yogendra Singh, Gunjan Sharma, Akhil Gupta, Vaibhav Bhargava et al. · 2021 · medRxiv
87. Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January–April 2021
    Catherine Anne Hogan, Agatha N. Jassem, Hind Sbihi, Yayuk Joffres, John R. Tyson, K Noftall, Marsha Taylor, Tracy Lee, Christopher D. Fjell, Amanda Wilmer et al. · 2021 · Emerging infectious diseases
88. Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
    Zhangkai Jason Cheng, Mingshan Xue, Peiyan Zheng, Jiali Lyu, Zhiqing Zhan, Haisheng Hu, Yong Zhang, Xiaohua Douglas Zhang, Baoqing Sun · 2021 · Vaccines
89. GAMBARAN TINGKAT KEPATUHAN MASYARAKAT DALAM PENERAPAN PROTOKOL KESEHATAN POST VAKSINASI COVID-19
    Agus Mulyawan, Rita Sekarsari, Nuraini Nuraini, Eriyono Budi · 2021 · Edu Dharma Journal Jurnal penelitian dan pengabdian masyarakat
90. Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infections During SARS-CoV-2
    Amanda Pfaff Smith, Evan Peter Williams, Taylor R. Plunkett, Muneeswaran Selvaraj, Lindey C. Lane, Lillian Zalduondo, Yi Xue, Peter Vogel, Rudragouda Channappanavar, Colleen Beth Jonsson et al. · 2022 · Frontiers in Immunology
91. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2
    Qiaoli Peng, Runhong Zhou, Na Liu, Hui Wang, Haoran Xu, Meiqing Zhao, Dawei Yang, Ka‐Kit Au, Haode Huang, Li Liu et al. · 2022 · Cellular and Molecular Immunology
92. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
    Ellen Bowden-Reid, Scott Ledger, Yuan Zhang, Francesca Di Giallonardo, Anupriya Aggarwal, Alberto Ospina Stella, Anouschka Akerman, Vanessa Milogiannakis, Gregory J. Walker, William D. Rawlinson et al. · 2023 · Antiviral Research
93. Local memory CD4 T cell niches in respiratory viral infection
    K. Pruner, M. Pepper · 2021 · Journal of Experimental Medicine
94. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
    Peng, Lei, Renauer, Paul A., Ökten, Arya, Fang, Zhenhao, Park, Jonathan J., Zhou, Xiaoyu, Lin, Qianqian, Dong, Matthew B., Filler, Renata, Xiong, Qiancheng et al. · 2022 · Cell Reports Medicine
95. An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern
    C. Paul Morris, Chun Huai Luo, Adannaya Amadi, Matthew C. Schwartz, Nicholas Gallagher, Stuart C. Ray, Andrew S Pekosz, Heba H. Mostafa · 2021 · Clinical Infectious Diseases
96. Discovery and characterization of a pan-betacoronavirus S2-binding antibody
    Nicole V. Johnson, Steven C. Wall, Kevin J. Kramer, Clinton Holt, Sivakumar Periasamy, Simone I. Richardson, Nelia P. Manamela, Naveenchandra Suryadevara, Emanuele Andreano, Ida Paciello et al. · 2024 · Structure
97. Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals
    Sabrina Racine‐Brzostek, Jim K. Yee, Ashley C. Sukhu, Yuqing Qiu, Sophie Rand, Paul Dylan Barone, Ying Hao, He S. Yang, Qing H. Meng, Fred S. Apple et al. · 2021 · JCI Insight
98. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study
    Andrea Carta, Claudio Conversano · 2021 · BMC Health Services Research
99. Effectiveness of 14 day quarantine strategy: Chinese experience of prevention and control
    Hongwei Tu, Keqi Hu, Meng Zhang, Yali Zhuang, Tie Song · 2021 · BMJ
100. Combination of Isothermal Recombinase-Aided Amplification and CRISPR-Cas12a-Mediated Assay for Rapid Detection of Major Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
     Hong-Qing Lin, Yuan-Hao Liang, L. Zou, Bai-Sheng Li, Jianhui Zhao, Hai-Ying Wang, Jiu-Feng Sun, Xiao-Ling Deng, Shixing Tang · 2022 · Frontiers in Microbiology